Cargando…

Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions

BACKGROUND: Little is known about the economic burden of treatment-resistant depression (TRD) in patients with physical conditions. OBJECTIVE: To assess health care resource utilization (HRU) and costs, work loss days, and related costs in patients with TRD and physical conditions versus patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhdanava, Maryia, Kuvadia, Harsh, Joshi, Kruti, Daly, Ella, Pilon, Dominic, Rossi, Carmine, Morrison, Laura, Lefebvre, Patrick, Nelson, Craig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391320/ https://www.ncbi.nlm.nih.gov/pubmed/32552362 http://dx.doi.org/10.18553/jmcp.2020.20017

Ejemplares similares

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug–Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression
por: Zhdanava, Maryia, et al.
Publicado: (2021)

Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA
por: Zhdanava, Maryia, et al.
Publicado: (2021)

Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
por: Pilon, Dominic, et al.
Publicado: (2022)

A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States
por: Zhang, Wenjie, et al.
Publicado: (2018)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation
por: Alberts, Mark, et al.
Publicado: (2023)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Venous Thromboembolism Recurrence Among Patients Who Abandon Oral Anticoagulant Therapy in the USA: A Retrospective Longitudinal Study
por: Alberts, Mark, et al.
Publicado: (2023)

Venous thromboembolism recurrence among one-and-done direct oral anticoagulant users: a retrospective longitudinal study
por: Alberts, Mark, et al.
Publicado: (2023)

How well do clinical and demographic characteristics predict Patient Health Questionnaire‐9 scores among patients with treatment‐resistant major depressive disorder in a real‐world setting?
por: Voelker, Jennifer, et al.
Publicado: (2021)

US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study
por: Pilon, Dominic, et al.
Publicado: (2019)

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab
por: Kavati, Abhishek, et al.
Publicado: (2018)

Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis
por: Pilon, Dominic, et al.
Publicado: (2019)

Correction: Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis
por: Pilon, Dominic, et al.
Publicado: (2021)

Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States
por: Williams, Paul V., et al.
Publicado: (2018)

Disease and Economic Burden Associated with Recurrent Pericarditis in a Privately Insured United States Population
por: Lin, David, et al.
Publicado: (2021)

Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
por: Pilon, Dominic, et al.
Publicado: (2017)

Economic Burden of Anemia in an Insured Population
por: Nissenson, Allen R., et al.
Publicado: (2005)

Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States
por: Kabadi, Shaum M., et al.
Publicado: (2019)

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
por: Pilon, Dominic, et al.
Publicado: (2017)

Medical Expenditures Associated With Diabetes Among Privately Insured U.S. Youth in 2007
por: Shrestha, Sundar S., et al.
Publicado: (2011)

Medical Expenditures Associated With Diabetes Acute Complications in Privately Insured U.S. Youth
por: Shrestha, Sundar S., et al.
Publicado: (2010)

Economic burden of paediatric-onset disabilities among young and middle-aged adults in the USA: a cohort study of privately insured beneficiaries
por: Whitney, Daniel, et al.
Publicado: (2019)

The Burden of Cervical Conization in Privately Insured Young and Mid-Adult Women in the United States
por: Saxena, Kunal, et al.
Publicado: (2023)

Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
por: Emond, Bruno, et al.
Publicado: (2018)

Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia
por: El Khoury, Antoine C., et al.
Publicado: (2020)

The clinical, economic, and patient‐centric burden of insomnia symptom severity in adults with major depressive disorder in the United States
por: Joshi, Kruti, et al.
Publicado: (2023)

Financial burden imposed on the insured patients for private treatment: Evidence from a state of Iran
por: Etemadi, Manal, et al.
Publicado: (2019)

Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market
por: Shih, Ya-Chen Tina, et al.
Publicado: (2021)

New Proposal of Private Insurance Program for Dementia Patients: Design of Sustainable Private Insurance Program in Korea
por: Park, Kun-Woo, et al.
Publicado: (2017)

Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate
por: Morrison, Laura, et al.
Publicado: (2023)

Growth in spending for substance abuse treatment services for the privately insured population
por: Thomas, Cindy Parks, et al.
Publicado: (2015)

Very high and low residual spenders in private health insurance markets: Germany, The Netherlands and the U.S. Marketplaces
por: McGuire, Thomas G., et al.
Publicado: (2020)

Government regulation of private health insurance
por: Motaze, Nkengafac V, et al.
Publicado: (2015)

Private dental insurance expenditure in Brazil
por: Cascaes, Andreia Morales, et al.
Publicado: (2018)

Government regulation of private health insurance
por: Motaze, Nkengafac Villyen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6vk99msa98pcdqg3lhost60p3d